title: Phospholipids as cardiovascular therapeutics.
abstract: A uniquely formulated soy phospholipid is being developed as a potential therapeutic for the treatment and prevention of heart disease. Three phase I and one phase I/II clinical trials have been completed with soy phosphatidylinositol (PI). The compound was shown to be safe in all trials and at doses over 5 g. Clinical studies have also shown early-stage efficacy to suggest that PI is able to raise plasma HDL-cholesterol and apolipoprotein A-I levels, and reduce triglyceride levels in humans. PI directly impacts plasma HDL levels through a MAPK stimulation of HDL production by the liver. Research has shown that the linoleic acid content of soy PI is critical to a peroxisome proliferator-activated receptor alpha dependent stimulation of HDL secretion. Soy-derived phospholipids uniquely affect cellular signaling and transcriptional processes. These lipids are safe and efficacious in humans and may therefore offer a novel therapeutic opportunity to treat cardiovascular disease.
authors.affiliation: Liponex Inc, Ottawa, Ontario K1Y 4W7, Canada.
authors.forename: Nihar R
authors.initials: NR
authors.lastname: Pandey
authors.forename: Daniel L
authors.initials: DL
authors.lastname: Sparks
mesh_terms: D000818:Animals; D002318:Cardiovascular Diseases / Q000188:drug therapy*; D006801:Humans; D007413:Intestinal Mucosa / Q000378:metabolism; D050356:Lipid Metabolism / Q000187:drug effects; D010743:Phospholipids / Q000378:metabolism / Q000627:therapeutic use*
chemical_list: D010743:Phospholipids